Last year we recruited our first two Team Leaders in a newly created role. One of them was Dr Charles de Bock. He was working in Belgium at the time but has since returned to Australia, and he took up the Team Leader position last month. Let’s find out something about him.
Groundbreaking research from our Leukaemia Biology Program has revealed how acute lymphoblastic leukaemia can become resistant to a class of anti-cancer drugs called glucocorticoids.
Twenty-six police officers and one cancer researcher took to the skies last Sunday to raise funds for childhood cancer research. The inaugural Great Cop Drop was inspired by Isla, a little girl diagnosed with leukaemia four years ago.
A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
One of our Clinical Research Fellows, Dr Toby Trahair, is taking part in the Tour de Cure Signature Tour 2018 which starts on Friday 27th April, raising money for cancer research by cycling 1110km from Mackay to Cairns.
Mackenzie was diagnosed with Acute Lymphoblastic Leukaemia (ALL) at just 9 years old. Her mum, Errin, has recently spoken about Mackenzie’s journey.
If doctors can reliably tell which children are most likely to get their leukaemia back, they can offer more intensive treatment options to prevent it.
Brain cancers are the leading disease-related cause of death in Australian children. In this article, first published in The Conversation, A/Prof David Ziegler explains what we can learn from improving childhood leukaemia survival.
We presented exciting results from preclinical drug testing at a cancer conference this week in the US.
In this second post in our series for Childhood Cancer Awareness month, see how we apply the basics about childhood cancer to search for better treatments.